277 related articles for article (PubMed ID: 29605800)
1. An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets.
Brixner D; Kaló Z; Maniadakis N; Kim K; Wijaya K
Value Health Reg Issues; 2018 Sep; 16():9-13. PubMed ID: 29605800
[TBL] [Abstract][Full Text] [Related]
2. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs) in Emerging Markets.
Brixner D; Maniadakis N; Kaló Z; Hu S; Shen J; Wijaya K
Value Health Reg Issues; 2017 Sep; 13():1-6. PubMed ID: 29073981
[TBL] [Abstract][Full Text] [Related]
3. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia.
Inotai A; Brixner D; Maniadakis N; Dwiprahasto I; Kristin E; Prabowo A; Yasmina A; Priohutomo S; Németh B; Wijaya K; Kalo Z
BMC Health Serv Res; 2018 Dec; 18(1):1003. PubMed ID: 30594250
[TBL] [Abstract][Full Text] [Related]
4. Guidance toward the implementation of multicriteria decision analysis framework in developing countries.
Inotai A; Nguyen HT; Hidayat B; Nurgozhin T; Kiet PHT; Campbell JD; Németh B; Maniadakis N; Brixner D; Wijaya K; Kaló Z
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):585-592. PubMed ID: 30092151
[TBL] [Abstract][Full Text] [Related]
5. Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework.
Angelis A; Linch M; Montibeller G; Molina-Lopez T; Zawada A; Orzel K; Arickx F; Espin J; Kanavos P
Soc Sci Med; 2020 Feb; 246():112595. PubMed ID: 31874372
[TBL] [Abstract][Full Text] [Related]
6. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
[TBL] [Abstract][Full Text] [Related]
7. Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: The Advance Value Framework.
Angelis A; Kanavos P
Soc Sci Med; 2017 Sep; 188():137-156. PubMed ID: 28772164
[TBL] [Abstract][Full Text] [Related]
8. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.
Goetghebeur MM; Wagner M; Khoury H; Levitt RJ; Erickson LJ; Rindress D
Med Decis Making; 2012; 32(2):376-88. PubMed ID: 21987539
[TBL] [Abstract][Full Text] [Related]
9. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
Diaby V; Lachaine J
Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
[TBL] [Abstract][Full Text] [Related]
10. Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.
Marsh K; IJzerman M; Thokala P; Baltussen R; Boysen M; Kaló Z; Lönngren T; Mussen F; Peacock S; Watkins J; Devlin N;
Value Health; 2016; 19(2):125-37. PubMed ID: 27021745
[TBL] [Abstract][Full Text] [Related]
11. Recommendation for a Pilot MCDA Tool to Support the Value-Based Purchasing of Generic Medicines in the UAE.
Farghaly MN; Al Dallal SAM; Fasseeh AN; Monsef NA; Suliman EAMA; Tahoun MA; Abaza S; Kaló Z
Front Pharmacol; 2021; 12():680737. PubMed ID: 34168564
[No Abstract] [Full Text] [Related]
12. [HERA-QUEST: HTA evaluation of generic pharmaceutical products to improve quality, economic efficiency, patient safety and transparency in drug product changes in hospitals].
Gyalrong-Steur M; Kellermann A; Bernard R; Berndt G; Bindemann M; Nusser-Rothermundt E; Amann S; Brakebusch M; Brüggmann J; Tydecks E; Müller M; Dörje F; Kochs E; Riedel R
Z Evid Fortbild Qual Gesundhwes; 2017 Apr; 121():5-13. PubMed ID: 28545614
[TBL] [Abstract][Full Text] [Related]
13. Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting.
Angelis A; Montibeller G; Hochhauser D; Kanavos P
BMC Med Inform Decis Mak; 2017 Oct; 17(1):149. PubMed ID: 29073892
[TBL] [Abstract][Full Text] [Related]
14. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.
Tony M; Wagner M; Khoury H; Rindress D; Papastavros T; Oh P; Goetghebeur MM
BMC Health Serv Res; 2011 Nov; 11():329. PubMed ID: 22129247
[TBL] [Abstract][Full Text] [Related]
15. The Use of MCDA in HTA: Great Potential, but More Effort Needed.
Marsh KD; Sculpher M; Caro JJ; Tervonen T
Value Health; 2018 Apr; 21(4):394-397. PubMed ID: 29680094
[TBL] [Abstract][Full Text] [Related]
16. Multi-criteria development and incorporation into decision tools for health technology adoption.
Poulin P; Austen L; Scott CM; Waddell CD; Dixon E; Poulin M; Lafrenière R
J Health Organ Manag; 2013; 27(2):246-65. PubMed ID: 23802401
[TBL] [Abstract][Full Text] [Related]
17. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) on the Polish pricing and reimbursement process of orphan drugs.
Kolasa K; Zwolinski KM; Kalo Z; Hermanowski T
Orphanet J Rare Dis; 2016 Mar; 11():23. PubMed ID: 26965710
[TBL] [Abstract][Full Text] [Related]
18. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
19. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries.
Oortwijn W; Mathijssen J; Banta D
Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829
[TBL] [Abstract][Full Text] [Related]
20. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
Holtorf AP; Gialama F; Wijaya KE; Kaló Z
Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
